The present study aimed to examine the influence of antibiotics (AB) on the clinical outcomes of Japanese patients treated with immune check point inhibitors (ICIs) for metastatic renal cell carcinoma (RCC) patients.
A total of 31 patients with metastatic RCC treated with ICIs from November 2016 to April 2019 were retrospectively reviewed and analyzed.
Five patients were treated with AB prior to ICIs treatment. Median progression free survival (PFS) of patients treated with AB vs. patients not treated with AB was 2.8 months and 18.4 months, respectively. The difference between PFS was statistically significant (p=0.0004). In multivariate analyses, AB use (p=0.0377) and presence of immune related adverse events (p=0.0042) were independent prognostic factors for PFS in association with ICIs therapy.
The use of AB before ICIs treatment was a predictor of poor ICIs response in metastatic RCC.
Anticancer research. 2019 Nov [Epub]
Kosuke Ueda, Satoru Yonekura, Naoyuki Ogasawara, Yoshihiro Matsunaga, Ryuji Hoshino, Hirofumi Kurose, Katsuaki Chikui, Keiichiro Uemura, Makoto Nakiri, Kiyoaki Nishihara, Mitsunori Matsuo, Shigetaka Suekane, Tsukasa Igawa
Department of Urology, Kurume University School of Medicine, Kurume, Japan ., Gustave Roussy Cancer Campus, Villejuif, France., Department of Urology, Kurume University School of Medicine, Kurume, Japan.